|
|
 |
Active Clinical Trials > Cancer Treatment and Symptom Management Trials |
|
Active Clinical Trials: GI- Hepatocellular
| Protocol | Title |
| 80802 | Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) (1786) |
| E1208 | A Phase III Randomized, Double-Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion (1758) |
| M10-963 | An Open-label, Randomized Phase III Study of the Efficacy and Tolerability of Linifanib (ABT-869) versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (HCC) (1760)-
Eligibility: click to view information
******SJMH PATIENTS ONLY*******
Inclusion Criteria:
Histologic or cytologic diagnosis with unresectable or metastatic HCC
Child Pugh Class A
ECOG performance status 0-1
Adequate hematologic, hepatic, and renal function
Exclusion Criteria:
Prior systemic (administered intravenously or orally rather than locoregionally) treatment for HCC.
Prior local therapy (including liver-directed therapy) within 4 weeks from entry
Untreated brain or meningeal metastases
Current treatment on another clinical trial
Pregnancy or breastfeeding
- Consent Forms: M10-963 GeneticResearch Consent, M10-963 Tissue Consent, M10-963 Main Consent
|
|
|
|
|
|
|
© 2010 MCRC. All rights reserved.
|
|
